Spero Therapeutics (SPRO) News Today → [URGENT] DO NOT Touch These AI Stocks! (From Weiss Ratings) (Ad) Free SPRO Stock Alerts $1.59 +0.02 (+1.27%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 6:59 PM | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business UpdateMay 16 at 4:05 PM | globenewswire.comSpero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor ConferenceMay 16 at 1:10 PM | markets.businessinsider.comBuy Rating Affirmed for Spero Therapeutics Amidst Drug Pipeline Progress and Strategic PartnershipsMay 16 at 8:41 AM | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $7.00 price objective on shares of Spero Therapeutics in a research note on Thursday.May 15, 2024 | globenewswire.comSpero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business UpdateMay 14, 2024 | msn.comSpero Therapeutics Q1 2024 Earnings PreviewMay 13, 2024 | americanbankingnews.comSpero Therapeutics (SPRO) Scheduled to Post Quarterly Earnings on WednesdayMay 10, 2024 | finance.yahoo.comShareholders in Spero Therapeutics (NASDAQ:SPRO) are in the red if they invested three years agoMay 8, 2024 | globenewswire.comSpero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024May 1, 2024 | globenewswire.comSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 28, 2024 | marketbeat.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Short Interest UpdateSpero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) was the target of a large decline in short interest in April. As of April 15th, there was short interest totalling 513,200 shares, a decline of 21.5% from the March 31st total of 653,800 shares. Based on an average daily trading volume, of 321,500 shares, the short-interest ratio is presently 1.6 days.April 4, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Rating Reiterated by Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating on shares of Spero Therapeutics in a research report on Thursday.March 20, 2024 | marketbeat.comHC Wainwright Comments on Spero Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:SPRO)Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - HC Wainwright issued their Q1 2024 earnings estimates for Spero Therapeutics in a research report issued on Monday, March 18th. HC Wainwright analyst R. Selvaraju anticipates that the company will post earnings of ($0.12) per share for the quMarch 19, 2024 | marketbeat.comHC Wainwright Weighs in on Spero Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:SPRO)Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Analysts at HC Wainwright issued their FY2025 earnings estimates for shares of Spero Therapeutics in a research report issued to clients and investors on Monday, March 18th. HC Wainwright analyst R. Selvaraju anticipates that the company willMarch 18, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Given Buy Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Spero Therapeutics in a research report on Monday.March 18, 2024 | markets.businessinsider.comSpero Therapeutics’ Robust Drug Pipeline and Positive Trial Advancements Prompt Buy RatingMarch 17, 2024 | finance.yahoo.comSpero Therapeutics, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This YearMarch 15, 2024 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comSpero Therapeutics, Inc.'s (NASDAQ:SPRO) Stock's On An Uptrend: Are Strong Financials Guiding The Market?March 14, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateMarch 14, 2024 | finance.yahoo.comQ4 2023 Spero Therapeutics Inc Earnings CallMarch 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Hold Rating for Spero Therapeutics (SPRO)March 13, 2024 | benzinga.comRecap: Spero Therapeutics Q4 EarningsMarch 13, 2024 | msn.comSpero Therapeutics GAAP EPS of $0.96 beats by $1.06, revenue of $73.5M beats by $54.87MMarch 13, 2024 | globenewswire.comSpero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business UpdateMarch 12, 2024 | msn.comSpero Therapeutics Q4 2023 Earnings PreviewMarch 7, 2024 | marketbeat.comSpero Therapeutics (SPRO) to Announce Quarterly Earnings on WednesdaySpero Therapeutics (NASDAQ:SPRO) will be releasing earnings after the market closes on Wednesday, March 13, Zacks reports.March 6, 2024 | globenewswire.comSpero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024February 28, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 28, 2024 | markets.businessinsider.comSpero Announces FDA Clearance Of IND Application For SPR206February 28, 2024 | finance.yahoo.comSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 28, 2024 | globenewswire.comSpero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial InfectionsFebruary 26, 2024 | finance.yahoo.comSpero Therapeutics to Present at Cowen’s 44th Annual Healthcare ConferenceFebruary 26, 2024 | globenewswire.comSpero Therapeutics to Present at Cowen's 44th Annual Healthcare ConferenceFebruary 17, 2024 | ca.finance.yahoo.comSPRO Apr 2024 1.000 callFebruary 17, 2024 | ca.finance.yahoo.comSPRO Apr 2024 2.000 putFebruary 10, 2024 | msn.comSpero Therapeutics Announces Chief Legal Officer’s ResignationFebruary 10, 2024 | marketbeat.comSpero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above 200-Day Moving Average of $1.31Spero Therapeutics (NASDAQ:SPRO) Stock Price Crosses Above Two Hundred Day Moving Average of $1.31February 9, 2024 | uk.investing.comSpero Therapeutics Inc (SPRO)February 6, 2024 | finance.yahoo.comSpero Therapeutics Inc CEO Sath Shukla Sells 75,994 SharesJanuary 31, 2024 | finance.yahoo.comSpero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 19, 2024 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?January 5, 2024 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Provides Corporate Update and 2024 OutlookJanuary 5, 2024 | msn.comSpero Therapeutics says cash and cash equivalents as of December 31 were about $76.3MJanuary 5, 2024 | finance.yahoo.comSpero Therapeutics Provides Corporate Update and 2024 OutlookJanuary 4, 2024 | markets.businessinsider.comSpero Therapeutics’ Promising Outlook: Clinical Milestones and Strategic GSK PartnershipJanuary 2, 2024 | finance.yahoo.comSpero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsJanuary 2, 2024 | finance.yahoo.comSpero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract InfectionsNovember 14, 2023 | finance.yahoo.comSpero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deSpero Therapeutics, Inc.: Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better. Click here to find out that this 8,788% cryptocurrency is. SPRO Media Mentions By Week SPRO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRO News Sentiment▼-0.170.42▲Average Medical News Sentiment SPRO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRO Articles This Week▼91▲SPRO Articles Average Week Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Oncolytics Biotech News Chimerix News Barinthus Biotherapeutics News ProPhase Labs News Vaccitech News BioXcel Therapeutics News Milestone Pharmaceuticals News Marinus Pharmaceuticals News Anixa Biosciences News Connect Biopharma News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SPRO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsShocking $16T Elon Musk Crypto LeakCrypto 101 MediaExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
